Related Experiment Video

Updated: Jun 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung

Xinjia He1, Tiantian Tian2, Yanjing Ma3

  • 1Department of Radiation Oncology, The Affiliated Hospital of Qingdao University and The First Clinical Medical College of Qingdao University, Qingdao City, Shandong Province, China.

Journal of Cancer Research and Therapeutics
|June 4, 2026
PubMed

Insights

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard for EGFR-mutated non-small-cell lung cancer (NSCLC). This review explores resistance mechanisms and immunotherapy strategies for improved outcomes in advanced NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are first-line treatments for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations.
  • Acquired resistance to EGFR-TKIs presents a significant challenge, leading to worse prognoses and necessitating novel therapeutic approaches.

Conclusions:

  • Effective management of EGFR-TKI-resistant NSCLC requires a comprehensive understanding of resistance mechanisms.
  • Further research is needed to elucidate the optimal use of ICIs in combination with or after EGFR-TKI therapy.
  • Personalized treatment strategies integrating immunotherapy hold promise for improving outcomes in advanced NSCLC.
Keywords:
EGFR mutationNSCLCimmunotherapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.